Actively Recruiting
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Led by Peking University People's Hospital · Updated on 2024-07-11
82
Participants Needed
1
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
CONDITIONS
Official Title
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis by hysteroscopy of atypical endometrial hyperplasia or well-differentiated early endometrial carcinoma (G1) without myometrial invasion
- Untreated patients or those with persistent lesions after one or two courses of progesterone therapy
- No signs of suspicious extrauterine involvement on enhanced MRI, CT, or ultrasound
- Desire to preserve reproductive function or uterus
- Good compliance with treatment and follow-up
You will not qualify if you...
- Allergy or contraindication to medroxyprogesterone acetate or atorvastatin
- Pregnancy or potential pregnancy
- Diagnosis of any cancer in the reproductive system
- Existing hyperlipidemia and use of lipid-lowering drugs
- Acute liver disease, liver tumor, or renal dysfunction
- History of severe diseases such as stroke, heart infarction, or thrombosis
- Other reproductive dysfunction factors
- Strong wish for uterine removal or other conservative treatments
- Smoking more than 15 cigarettes per day
- Drinking more than 20 grams of alcohol daily
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wang Jianliu
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
W
WANG JIANLIU, PhD/MD
CONTACT
H
HE YIJIAO, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here